FDA and PTO look to shore up in­con­sis­ten­cies around phar­ma patents

Build­ing off Pres­i­dent Joe Biden’s ex­ec­u­tive or­der from Ju­ly 2021, the FDA and Patent and Trade­mark Of­fice are look­ing to forge a tighter bond on every­thing from “skin­ny” gener­ic drug la­bels to bet­ter train­ing patent ex­am­in­ers.

As part of build­ing this clos­er re­la­tion­ship, the FDA and USP­TO on Jan. 23, 2023, will hold a pub­lic lis­ten­ing ses­sion, of­fer­ing room for com­ment on how the two agen­cies can work more in tan­dem, ac­cord­ing to a Fed­er­al Reg­is­ter no­tice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER